Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation. (2020)

• Record Type: Journal Article
• Authors: Oi, Hajime; Suzuki, Atsushi; Yamano, Yasuhiko; Yokoyama, Toshiki; Matsuda, Toshiaki; Kataoka, Kensuke; Suzuki, Yasuhiko; Kimura, Tomoki; Kondoh, Yasuhiro
• Is Part Of: Respiratory medicine case reports. Volume 31(2020)
• Publication Date: 2020
• Subjects: NPPV non-invasive positive pressure ventilation -- DLI drug-induced lung injury -- 5-ASA 5-aminosalicylic acid -- UC ulcerative colitis -- WBC white blood cell -- CRP c-reactive protein -- KL-6 Krebs von den Lungen-6 -- SP-D surfactant protein-D -- PaCO2 partial pressure of carbon dioxide -- PaO2 partial pressure of oxygen -- CT computed tomography -- BAL bronchoalveolar lavage -- BALF bronchoalveolar lavage fluid -- TBLB transbronchial lung biopsy -- ARDS acute respiratory distress syndrome -- PEEP positive end-expiratory pressure; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2020.101157
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Drug-induced lung injury (DLI) has become more common because of the increasing number of therapeutic agents in use. Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is one of the key drugs for the treatment of ulcerative colitis (UC). Although mesalazine-induced lung injury has been previously reported, few cases have included severe respiratory failure. In this report, we present a case of mesalazine-induced lung injury with severe respiratory failure, which was improved by discontinuation of mesalazine and introduction of corticosteroid therapy and ventilation support with non-invasive positive pressure ventilation (NPPV). We also review the previous literature on mesalazine-induced lung injury.